Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.
Summary of Financial Statements for the Nine Months
Ended December 31, 2021 [IFRS] (Consolidated)
February 7, 2022 | |
Company name: | JMDC Inc. |
Listing: | Tokyo Stock Exchange |
Stock code: | 4483 |
URL: | https://www.jmdc.co.jp/eng/ |
Representative: | Yosuke Matsushima, President and CEO |
Inquiries: | Yuta Yamamoto, Vice President and CFO |
TEL: | +81-3-5733-5010 |
Scheduled date to file quarterly securities report: | February 14, 2022 |
Scheduled date to commence dividend payments: | - |
Preparation of supplementary material on quarterly financial results: Yes | |
Holding of quarterly financial results presentation meeting: | None |
(Yen amounts are rounded down to millions, unless otherwise noted.)
1. Consolidated financial results for the first nine months of the fiscal year ending March 31, 2022 (from April 1, 2021 to December 31, 2021)
(1) Consolidated operating results (cumulative) | (Percentages indicate year-on-year changes.) | ||||||||||||
Revenue | Operating profit | Profit before tax | Profit | ||||||||||
Nine months ended | Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % | |||||
December 31, 2021 | 15,679 | 35.1 | 3,417 | 41.0 | 3,408 | 41.6 | 2,279 | 44.4 | |||||
December 31, 2020 | 11,606 | 34.1 | 2,424 | 63.7 | 2,406 | 67.2 | 1,578 | 62.3 | |||||
Profit attributable to | Total comprehensive | Basic earnings | Diluted earnings | ||||||||||
owners of parent | income | per share | per share | ||||||||||
Nine months ended | |||||||||||||
Millions of yen | % | Millions of yen | % | Yen | Yen | ||||||||
December 31, 2021 | 2,280 | 44.5 | 2,279 | 44.5 | 40.61 | 38.27 | |||||||
December 31, 2020 | 1,578 | 62.3 | 1,577 | 62.2 | 30.12 | 28.98 | |||||||
Reference: EBITDA | Nine months ended December 31, 2021 | ¥4,580 million [39.5%] | |||||||||||
Nine months ended December 31, 2020 | ¥3,284 million [45.9%] |
Notes: 1. The Company conducted a 2-for-1 share split of its ordinary shares on October 1, 2020. Basic earnings per share and diluted earnings per share have been calculated assuming that the share split was conducted at the beginning of the previous fiscal year.
2. EBITDA: Operating profit + Depreciation and amortization ± Other income and/or expenses
- Consolidated financial position
Equity attributable to | Ratio of equity | |||
Total assets | Total equity | attributable to owners | ||
owners of parent | ||||
of parent | ||||
As of | Millions of yen | Millions of yen | Millions of yen | % |
December 31, 2021 | 60,393 | 30,154 | 30,154 | 49.9 |
March 31, 2021 | 58,264 | 28,250 | 28,250 | 48.5 |
Note: During the third quarter ended December 31, 2021, the Company finalized the provisional accounting treatment for business combinations. As a result, figures for the fiscal year ended March 31, 2021 reflect the finalization of the provisional accounting treatment.
2. Cash dividends
Annual dividends | ||||||
First quarter-end | Second quarter-end | Third quarter-end | Fiscal year-end | Total | ||
Yen | Yen | Yen | Yen | Yen | ||
Fiscal year ended | - | 0.00 | - | 0.00 | 0.00 | |
March 31, 2021 | ||||||
Fiscal year ending | - | 0.00 | - | |||
March 31, 2022 | ||||||
Fiscal year ending | 0.00 | 0.00 | ||||
March 31, 2022 | ||||||
(Forecast) | ||||||
Note: Revisions to the forecast of cash dividends most recently announced: None |
3. Consolidated earnings forecasts for the fiscal year ending March 31, 2022 (from April 1, 2021 to March 31, 2022)
(Percentages indicate year-on-year changes.)
Profit | Basic | |||||||||||||
Revenue | Operating profit | Profit before tax | Profit | attributable to | earnings per | |||||||||
owners of parent | share | |||||||||||||
Millions | % | Millions | % | Millions | % | Millions | % | Millions | % | Yen | ||||
of yen | of yen | of yen | of yen | of yen | ||||||||||
Fiscal year ending | 21,550 | 28.5 | 4,800 | 29.9 | 4,750 | 30.6 | 3,250 | 31.3 | 3,250 | 31.3 | 58.79 | |||
March 31, 2022 | ||||||||||||||
Note: Revisions to the earnings forecasts most recently announced: None | ||||||||||||||
Reference: EBITDA | Fiscal year ending March 31, 2022 (Forecast) | ¥6,400 million [31.5%] |
* Notes
- Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in the change in scope of consolidation): None
- Changes in accounting policies and changes in accounting estimates
(i) Changes in accounting policies required by IFRS: | None |
(ii) Changes in accounting policies due to other reasons: | None |
(iii) Changes in accounting estimates: | None |
(3) Number of issued shares (ordinary shares)
(i) Total number of issued shares at end of the period (including treasury shares)
As of December 31, 2021 | 56,433,008 shares |
As of March 31, 2021 | 55,935,808 shares |
(ii) Number of treasury shares at end of the period
As of December 31, 2021 | 459 shares |
As of March 31, 2021 | 366 shares |
- Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)
For the nine months ended December 31, 2021 | 56,167,660 shares |
For the nine months ended December 31, 2020 | 52,420,178 shares |
Note: The Company conducted a 2-for-1 share split of its ordinary shares on October 1, 2020. The "average number of shares outstanding during the period" has been calculated assuming that the share split was conducted at the beginning of the previous fiscal year.
- Quarterly financial results reports are exempt from quarterly reviews conducted by certified public accountants or an audit corporation.
-
Proper use of earnings forecasts, and other special items Notes on forward-lookingstatements
The forward-looking statements, including earnings forecasts, contained in these materials are based on information currently available to the Company and on certain assumptions deemed to be reasonable by the Company. Actual business and other results may differ substantially due to various factors. For details regarding matters related to earnings forecasts, please refer to page 5 of the attached materials.
How to obtain supplementary documents on financial results
Supplementary documents on financial results are released via TDnet on the same day.
JMDC Inc. (4483)
Attached Material Index | ||
1. Qualitative information regarding financial results for the nine months ended December 31, 2021 | ||
(2) | Explanation of financial position........................................................................................................ | 4 |
(3) | Explanation of consolidated earnings forecasts and other forward-looking statements..................... | 5 |
2. Condensed quarterly consolidated financial statements and significant notes thereto ............................. | 6 | |
(1) | Condensed quarterly consolidated statement of financial position .................................................... | 6 |
(2) | Condensed quarterly consolidated statement of profit or loss and condensed quarterly consolidated | |
statement of comprehensive income .................................................................................................. | 7 | |
(3) | Condensed quarterly consolidated statement of changes in equity .................................................... | 9 |
(4) | Condensed quarterly consolidated statement of cash flows ............................................................. | 11 |
(5) | Notes to condensed quarterly consolidated financial statements...................................................... | 12 |
Notes on going concern assumption................................................................................................. | 12 | |
Segment information ........................................................................................................................ | 12 | |
Significant subsequent events........................................................................................................... | 14 |
- 1 -
JMDC Inc. (4483)
1. Qualitative information regarding financial results for the nine months ended December 31, 2021
-
Explanation of operating results
JMDC Inc. (the "Company") is promoting the health of citizens, and delivering increased value of medical service providers and helping optimize their operations through gathering diverse data on the Japanese healthcare industry and thus benefiting society, with the aim of realizing a sustainable healthcare system by leveraging data and ICT.
In the Healthcare-Big Data segment, to promote the health services of health insurance associations, we provide analysis services for data held by health insurance associations as well as personal health record (PHR) services developed by the Company. We also provide services such as medical data analysis and medical factoring to medical institutions as well as medicine databases. Furthermore, we have created a database of anonymously processed information in the course of pursuing this business and are promoting scientific and industrial applications of this data.
In the Tele-medicine segment, we provide a matching service that connects medical institutions lacking a sufficient number of radiologists with contracted radiologists using a remote image interpretation system, as well as an ASP service that connects medical institutions with radiologists via the cloud to enable remote diagnostic imaging.
In the Dispensing Pharmacy Support segment, we develop and sell systems such as receipt computers and electronic medication history systems to health insurance pharmacies, and also conduct tests of our own systems as we operate our own dispensing pharmacies.
Operating results for the nine months ended December 31, 2021 are as follows. (Operating results)
(Millions of yen) | |||||||
8th fiscal year | 9th fiscal year | ||||||
Category | Nine months ended | Nine months ended | YoY change | ||||
December 31, 2020 | December 31, 2021 | ||||||
Revenue | 11,606 | 15,679 | 4,073 | 35.1% | |||
Operating profit | 2,424 | 3,417 | 993 | 41.0% | |||
EBITDA [Margin] | 3,284 | [28.3%] | 4,580 | [29.2%] | 1,296 | 39.5% |
(Segment results)
(Millions of yen)
8th fiscal year | 9th fiscal year | |||||||
Category | Nine months ended | Nine months ended | YoY change | |||||
December 31, 2020 | December 31, 2021 | |||||||
Healthcare-Big | Segment revenue | 6,753 | 9,883 | 3,130 | 46.3% | |||
Data | Segment profit [ratio] | 2,316 | [34.3%] | 3,412 | [34.5%] | 1,096 | 47.3% | |
Tele-medicine | Segment revenue | 3,000 | 3,370 | 370 | 12.3% | |||
Segment profit [ratio] | 918 | [30.6%] | 1,200 | [35.6%] | 282 | 30.7% | ||
Dispensing | Segment revenue | 1,950 | 2,567 | 617 | 31.6% | |||
Pharmacy Support | Segment profit [ratio] | 241 | [12.4%] | 209 | [8.1%] | (32) | (13.3)% | |
Adjustment | Segment revenue | (97) | (143) | (46) | - | |||
Segment profit | (192) | (242) | (50) | - | ||||
Total | Revenue | 11,606 | 15,679 | 4,073 | 35.1% | |||
EBITDA [margin] | 3,284 | [28.3%] | 4,580 | [29.2%] | 1,296 | 39.5% | ||
Note: EBITDA is an objective indicator for judging the achievement of the JMDC Group's management policies and strategies or management objectives. The JMDC Group uses EBITDA to measure the performance of each segment and believes that it is a useful and necessary measure to assess the Group's performance more effectively. The formulas for calculating EBITDA and EBITDA margin are as follows.
EBITDA: | Operating profit + Depreciation and amortization ± Other income and/or expenses |
EBITDA margin: | EBITDA / Revenue x 100 |
- 2 -
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
JMDC Inc. published this content on 07 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 February 2022 06:07:03 UTC.